The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 09, 2021

Filed:

Jun. 30, 2017
Applicant:

Industry-university Cooperation Foundation Hanyang University, Seoul, KR;

Inventors:

Yong-Hee Kim, Seoul, KR;

Hyung Jin Kim, Goyang-si, KR;

Jee Young Chung, Goyang-si, KR;

Yoon Sung Song, Seongnam-si, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/04 (2006.01); A61P 3/04 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0025 (2013.01); A61K 48/00 (2013.01); A61K 48/0016 (2013.01); A61P 3/04 (2018.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01);
Abstract

The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4+FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex. In this way, it is possible to achieve an excellent therapeutic effect on obesity which targets only adipocytes without cytotoxicity.


Find Patent Forward Citations

Loading…